2026 | News and Events | Clinical | Eurofins-Viracor | Clinical

Providing Insights Into Cancer Treatment Success

CAR T‑cell therapy is a leading immunotherapeutic option for relapsed or treatment‑resistant B‑cell cancers, using genetically modified T‑cells to recognize and eliminate malignant B‑cells. Eurofins Viracor’s ExPeCT™ CAR T‑Cell Persistence Assays provide clinicians with a validated, quantitative tool to monitor CAR T‑cell expansion and persistence, supporting informed treatment decisions and long‑term remission assessment.

ATC 2026 - American Transplant Congress

Eurofins Viracor will be exhibiting at ATC 2026, June 20-24, 2026, Booth #231, Thomas M. Menino Convention Center, Boston, MA

ISHLT 2026 - The International Society for Heart & Lung Transplantation

Eurofins Viracor will exhibit at ISHLT 2026 in Toronto, connecting attendees with cutting-edge heart and lung transplantation science, industry innovations, and networking opportunities.

Eurofins Viracor Launches ExPeCT™ anti-CD19 (obe-cel) CAR T-Cell Assay to Advance Proactive Monitoring in Next-Generation Immunotherapy

Eurofins Viracor has launched the ExPeCT™ anti-CD19 (obe-cel) CAR T-cell assay, a new diagnostic solution designed to support proactive monitoring of next-generation CAR T-cell therapies. This non-invasive blood test enables real-time assessment of CAR T-cell expansion and persistence, delivering results in approximately 24 hours after specimen receipt. Developed specifically for testing obecabtagene autoleucel (obe-cel), the assay helps clinicians gain timely, validated insights to support informed therapy decisions.

Transforming CAR T Monitoring: The Power of the ExPeCT AntiCD19 (obe-cel) Assay

Improve CAR T Monitoring - ExPeCT Anti‑CD19 (obe‑cel) Test

Discover how the ExPeCT anti‑CD19 (obe‑cel) assay enables precise CAR T‑cell expansion and persistence monitoring, delivering faster insights to guide patient care.

Eurofins Viracor Launches Assays for Pneumococcal Antibody Detection, Expanding Serotype Coverage to Support Immunocompromised Patient Care

Eurofins Viracor has launched multiplex pneumococcal antibody assays covering all vaccine serotypes, including PCV21. The 32‑serotype panel improves accuracy and supports personalized immunity monitoring. This advancement reinforces the company’s leadership in immunology diagnostics.

Tandem Meetings 2026 - Transplantation & Cellular Therapy Meetings

Eurofins Viracor will be exhibiting at the Tandem Meetings 2026 - Transplantation & Cellular Therapy of ASTCT & CIBMTR, February 4 - 7, Booth #511 at the Salt Palace Convention Center, Salt Lake City, Utah.